ALBUCLATE Trademark

Trademark Overview

On Thursday, February 7, 2008, a trademark application was filed for ALBUCLATE with the United States Patent and Trademark Office. The USPTO has given the ALBUCLATE trademark a serial number of 79051055. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Wednesday, February 7, 2018. This trademark is owned by CSL Behring GmbH. The ALBUCLATE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products for the prevention and/or treatment of blood or bleeding disorders; blood plasma; blood proteins for therapeutic use; blood clotting agents for medical use
albuclate

General Information

Serial Number79051055
Word MarkALBUCLATE
Filing DateThursday, February 7, 2008
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateWednesday, February 7, 2018
Registration Number3598681
Registration DateTuesday, March 31, 2009
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 13, 2009

Trademark Statements

Goods and ServicesPharmaceutical products for the prevention and/or treatment of blood or bleeding disorders; blood plasma; blood proteins for therapeutic use; blood clotting agents for medical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 6, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCSL Behring GmbH
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressDE
Party NameCSL Behring GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressDE
Party NameCSL Behring GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressDE

Trademark Events

Event DateEvent Description
Friday, August 31, 2018NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Friday, August 31, 2018DEATH OF INTERNATIONAL REGISTRATION
Friday, April 21, 2017TOTAL INVALIDATION PROCESSED BY THE IB
Friday, July 8, 2016TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Friday, July 8, 2016INVALIDATION PROCESSED
Wednesday, July 6, 2016TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Thursday, February 25, 2016NEW REPRESENTATIVE AT IB RECEIVED
Friday, November 6, 2015CANCELLED SECTION 71
Sunday, February 10, 2013NEW REPRESENTATIVE AT IB RECEIVED
Saturday, January 12, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, July 14, 2009FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, July 14, 2009FINAL DISPOSITION PROCESSED
Tuesday, June 30, 2009FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, March 31, 2009REGISTERED-PRINCIPAL REGISTER
Tuesday, January 13, 2009PUBLISHED FOR OPPOSITION
Wednesday, December 24, 2008NOTICE OF PUBLICATION
Monday, December 8, 2008LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, December 5, 2008APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 5, 2008TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 5, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 5, 2008ASSIGNED TO LIE
Friday, November 21, 2008TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 13, 2008REFUSAL PROCESSED BY IB
Thursday, May 22, 2008NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, May 22, 2008REFUSAL PROCESSED BY MPU
Thursday, May 22, 2008NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, May 21, 2008NON-FINAL ACTION WRITTEN
Monday, May 19, 2008ASSIGNED TO EXAMINER
Friday, April 11, 2008NEW APPLICATION ENTERED IN TRAM
Thursday, April 10, 2008SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

albuclate blood therapeutic proteins clotting medical agents plasma disorders products prevention